Valuation: Revance Therapeutics, Inc.

Market Cap 319M 276M 261M 236M 443M 30.47B 447M 3.11B 1.2B 15.51B 1.2B 1.17B 49.22B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 470M 444M 402M 755M 51.92B 761M 5.3B 2.04B 26.42B 2.04B 2B 83.86B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
17.36
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-78.55% 383M
+1.57%-4.11%+41.74%-3.93% 78.04B
+1.89%+0.78%+523.95%+35.09% 57.48B
+2.68%-1.68%-17.44%-36.27% 57.4B
+0.35%-1.87%-11.03%+27.74% 48.81B
+2.38%-0.05%+1.49%+157.52% 45.5B
+0.10%-1.57%+50.05%-15.06% 32.08B
+0.59%-3.60%+47.04%+93.65% 24.62B
+3.53%-5.42%-1.02%+170.53% 20.77B
+2.24%-1.45%+66.12%+103.91% 15.75B
Average +1.36%-3.28%+70.09%+45.46% 38.08B
Weighted average by Cap. +1.37%-3.44%+93.71%+39.70%

Financials

2022 2023
Net sales 133M 115M 108M 98.18M 184M 12.67B 186M 1.29B 498M 6.45B 498M 487M 20.46B 234M 203M 191M 173M 325M 22.36B 328M 2.28B 879M 11.38B 879M 860M 36.12B
Net income -356M -309M -291M -264M -495M -34.05B -499M -3.48B -1.34B -17.33B -1.34B -1.31B -55.01B -324M -280M -265M -240M -450M -30.95B -454M -3.16B -1.22B -15.75B -1.22B -1.19B -50B
Net Debt 77.76M 67.32M 63.54M 57.59M 108M 7.43B 109M 758M 292M 3.78B 292M 286M 12B 225M 194M 183M 166M 312M 21.45B 314M 2.19B 843M 10.92B 843M 825M 34.65B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!